Researchers at Lund University have unexpectedly discovered that an old cancer drug can be used to prevent rejection of transplanted tissue.
The researchers now have high hopes that their discovery could lead to new treatments for both transplant patients and patients with autoimmune diseases.
The researchers behind the study, which has been published in the scientific journal PLOS ONE, work at the Rausing Laboratory, Lund University, where they have conducted research on brain tumours over many years.
“Our group were studying the effects of the old tumour drug Zebularine, developed in the USA in the 1960s, and by chance we discovered that it had completely unexpected effects on the immune system”, says Leif Salford, Senior Professor of Neurosurgery.
“It turned out that Zebularine has the ability to subdue the reaction of the body’s immune system. This could be important in situations where tissue or organs are transplanted. We also think it could be used to curb the body’s attacks on its own tissue in autoimmune diseases, for instance type 1 diabetes or rheumatoid arthritis”, says Dr Nittby.
In studies on animals, the researchers used rats that were made diabetic. The researchers transplanted the islets of Langerhans – cell groups in the pancreas producing insulin – from healthy rats from another kind of rat into those with diabetes. The diabetic rats were divided into two groups; one group were treated with Zebularine and the other, the control group, did not receive any treatment. The diabetic rats that were treated with Zebularine survived for a significantly longer period than the untreated rats.
“It is very interesting that we only treated them with Zebularine for two weeks, but the effects of the treatment could be observed throughout the 90-day follow-up period.
“The findings are very exciting and are a sign that the immune system was not just generally suppressed, but that the treatment was more targeted. Neither did we see any signs of side-effects”, said Dr Nittby.
The researchers are now working intensively to further refine the treatment. The next step is to teach certain cells in the immune system – the dendritic cells – to accept certain specific proteins using the Zebularine treatment.
This would mean that the treatment could be targeted even more.
“If we succeed with that, we believe it could be of clinical significance both to prevent rejection of transplanted organs and to stop the body attacking its own tissue in autoimmune diseases.
The Latest on: Zebularine
- TiGenix : Interview with Neil Thomas, Chief Business Officer in Idogen on November 30, 2016 at 4:01 am
During the last period Idogen has filed several patent applications, protecting potential follow-up drugs with a novel or similar mechanism to zebularine. This is important work, as it further protects our methodologies from potential competition ... […]
- Genetic signature of liver cancer cell response to zebularine to predict therapeutic response on November 3, 2010 at 5:00 pm
In vitro and mouse studies identified a gene signature response to zebularine that could help predict therapeutic outcomes in liver cancer. In hepatocellular carcinoma (HCC) cell lines, a gene expression signature of response to the DNA methylation ... […]
- Special Online Collection: Epigenetics on October 28, 2010 at 5:00 pm
In the 29 October 2010 issue, Science delves into various aspects of epigenetics, which involves the inheritance of variation above and beyond changes in DNA sequence. Reviews and Perspectives examine various epigenetic mechanisms and their roles in ... […]
- Cancer Drug Targets Tumor Cells on August 25, 2004 at 5:00 pm
The drug a DNA methylation inhibitor called zebularine is better at inhibiting cell growth in cancer cells, said Peter Jones, director of the USC/Norris Comprehensive Cancer Center and the principal investigator on the study. In a study of ... […]
via Google News and Bing News